Years into a government probe over alleged generic drug price fixing, investigators have expanded the scope to include 300 drugs and 16 companies, an official told The Washington Post.
Federal investigators have been looking into possible price fixing at top generic drugmakers for years, and on Friday, a top Department of Justice official signaled what his agency might do next.